EMA Recommends Extension of Therapeutic Indications for Acalabrutinib By Ogkologos - June 18, 2025 698 0 Facebook Twitter Google+ Pinterest WhatsApp A new indication concerns the treatment of adult patients with previously untreated CLL in combination with venetoclax Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR A Combination of Oral Mezigdomide Plus Dexamethasone Shows Promising Efficacy in... September 28, 2023 A Combination of Amivantamab and Lazertinib Shows Durable Clinical Activity in... October 10, 2023 Adding Apalutamide to Perioperative ADT Associated with Better Outcomes of Radical... June 3, 2026 PFS Non-inferior with Fixed-Duration Treatment with Venetoclax-Obinutuzumab or Venetoclax-Ibrutinib to Continuous... December 17, 2025 Load more HOT NEWS Remodeled CAR T-Cell Therapy Reduces Side Effects in First Clinical Trial FDA Approves New Initial Treatment Option for Some Metastatic Prostate Cancers Cómo compartir los resultados de las pruebas genéticas con la familia Opinion: ‘We’re speaking with One Cancer Voice, but is anyone listening?’
